[{"bbox": [93, 100, 368, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [93, 167, 1557, 332], "category": "Table", "text": "<table><thead><tr><td>Types of transactions</td><td>Weighted average cost of acquisition (₹ per Equity Shares)</td><td>Floor price* (i.e. ₹ [•])</td><td>Cap Price* (i.e. ₹ [•])</td></tr></thead><tbody><tr><td>Weighted average cost of acquisition of primary issuances/ secondary transactions as per paragraph 8(c) above</td><td>0.35</td><td>[•] times</td><td>[•] times</td></tr></tbody></table>"}, {"bbox": [93, 336, 1560, 527], "category": "Text", "text": "Note:\n*^There were no primary/new issue of shares (equity/convertible securities) as mentioned in paragraph 8(a) above, in last 18 months from the date of this Draft Red Herring Prospectus.\n*^^There were no secondary transaction of shares as mentioned in paragraph 8(b) above, in last 18 months from the date of this Draft Red Herring Prospectus.\n* To be updated at Prospectus stage."}, {"bbox": [93, 559, 1560, 652], "category": "Text", "text": "Detailed explanation for Issue Price/ Cap Price being [•] times of WACA of primary issuances/ secondary transactions of Equity Shares (as disclosed above) along with our Company's KPIs in view of the external factors which may have influenced the pricing and financial ratios for Fiscals 2025, 2024 and 2023:"}, {"bbox": [93, 687, 143, 717], "category": "Text", "text": "[•]*"}, {"bbox": [93, 749, 675, 780], "category": "Text", "text": "*To be included upon finalization of the Price Band."}, {"bbox": [93, 813, 1560, 908], "category": "Text", "text": "This is a Book Built Issue and the price band for the same shall be published 2 working days before opening of the Issue in all editions of the English national newspaper [•], all editions of Hindi national newspaper [•] and one Regional newspaper [•] where the registered office of the company is situated each with wide circulation."}, {"bbox": [93, 942, 1560, 1100], "category": "Text", "text": "The Price Band/ Floor Price/ Issue Price shall be determined by our Company in consultation with the BRLMs and will be justified by us in consultation with the BRLMs on the basis of the above information. Investors should read the above mentioned information along with **\"Our Business\", \"Risk Factors\" and \"Restated Financial Statements\"** on pages 123, 29 and 179 respectively, to have a more informed view. The trading price of the Equity Shares of our Company could decline due to the factors mentioned in **\"Risk Factors\"** or any other factors that may arise in the future and you may lose all or part of your investments."}]